USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
MEDIMMUNE, INC.
Address:
35 WEST WATKINS MILL RD
Gaithersburg, MD 20878
Phone:
N/A
URL:
N/A
EIN:
N/A
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $1,026,806.00 14
SBIR Phase II $2,426,651.00 4

Award List:

DEVELOPMENT OF A NEW MAMMALIAN CELL EXPRESSION SYSTEM

Award Year / Program / Phase:
1989 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

MALARIA VACCINE DEVELOPMENT

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$49,000.00
Agency:
HHS
Principal Investigator:
James F Young
Abstract:
Malaria is one of the most widespread infectious diseases of humans and threatens almost half of the world's population. currently, there are an estimated 350+ million acute cases worldwide each year, and approximately 1 to 2 million infants and young children die in africa alone because of the… More

SURROGATE ASSAY FOR B19 PARVOVIRUS SERUM NEUTRALIZATION

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$49,000.00
Agency:
HHS
Principal Investigator:
G P Bansal
Abstract:
Parvovirus b19 is implicated as a cause of many human disease syndromes. a vaccine for immunization against b19 virus infection is urgently needed in certain of these situations, but, in others, immunoglobulin therapy may prove a more feasible and appropriate strategy. current commercial… More

USE OF RECOMBINANT MYCOBACTERIAL VACCINES FOR MALARIA

Award Year / Program / Phase:
1990 / SBIR / Phase I
Award Amount:
$49,000.00
Agency:
HHS
Principal Investigator:
Vidal F De La Cruz
Abstract:
Malaria, one of the most widespread infectious diseases of humans, threatens almost half the world's population. currently, there are an estimated 350+ million acute cases worldwide each year, and approximately 1 to 2 million infants and young children die in africa alone because of the disease.… More

DEVELOPMENT OF A NEW MAMMALIAN CELL EXPRESSION SYSTEM

Award Year / Program / Phase:
1991 / SBIR / Phase II
Award Amount:
$500,000.00
Agency:
HHS
Principal Investigator:
Abstract:
Numerous expression systems exist for the production of proteins in both prokaryotic and eukaryotic cells. each system has its own set of advantages as well as shortcomings. the need remains for a mammalian cell expression system that can achieve high-level target gene expression, correctly process… More

HYPEREXPRESSION SYSTEM FOR RECOMBINANT BCG VACCINES

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Charles K Stover
Abstract:
Bcg, a live attenuated strain of mycobacterium bovis, offers a number a distinct advantages as a live recombinant vaccine vehicle. these advantages include potent adjuvant activity and ahistory of safe use in humans as a tuberculosis vaccine. major genetic obstacles impeding the development of bcg… More

HUMAN-MURINE CHIMERIC ANTIBODIES VS. RESPIRATORY SYNCYTIAL VIRUS

Award Year / Program / Phase:
1992 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Leslie S Johnson
Abstract:
N/a

HUMAN-MURINE CHIMERIC ANTIBODIES VS. RESPIRATORY SYNCYTIAL VIRUS

Award Year / Program / Phase:
1993 / SBIR / Phase II
Award Amount:
$428,150.00
Agency:
HHS
Principal Investigator:
Leslie S Johnson
Abstract:
Respiratory syncytial virus (rsv) is responsible for yearly epidemics of bronchiolitis and pneumonia in infants and young children. at risk of serious rsv morbidity are children with underlying disease, bronchopulmonary dysplasia and other pulmonary diseases, various congenitalor acquired… More

H. Influenzae Vaccine Based On Recombinant BCG

Award Year / Program / Phase:
1993 / SBIR / Phase I
Award Amount:
$50,000.00
Agency:
HHS
Principal Investigator:
Mark S. Hanson
Abstract:
BCG (Bacille Calmette-Guerin), an attenuated strain of Mycobacterium bovis that is used in viable form to vaccinate humans against tuberculosis, offers a number of unique advantages for development as a multivalent vaccine vehicle. Recently, versatile vectors for the expression of heterologous… More

Monoclonal Antibodies to Respiratory Syncytial Virus

Award Year / Program / Phase:
1994 / SBIR / Phase I
Award Amount:
$81,000.00
Agency:
HHS
Principal Investigator:
Geetha Bansal
Abstract:
Respiratory syncytial virus (RSv) is the primary etiologic agent of pediatric respiratory tractinfection. In premature infants and children with bronchopulmonary dysplasia or congenital heartdisease, RSv induced pneumonia and bronchiolitis cause significant morbidity and mortality. ProphylacticRSv… More

CD4 Based Therapeutic Vaccine for HIV

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$99,983.00
Agency:
HHS
Principal Investigator:
David Cassatt
Abstract:
An effective therapeutic vaccine for HIV should be capable of reducing viral load and spread of infprevent the onset of AIDS. In an SIV-rhesus macaque model, immunization with a recombinant, solubleCD4 molecule (rsCD4) induced an anti-CD4 response that reduced viral load and rendered PBLs from… More

Lyme Disease Vaccine Using Gonococcal Blebs

Award Year / Program / Phase:
1995 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
John Cairns
Abstract:
The investigators will develop a system in which OspA, an antigen known to induce protective immuneagainst Borrelia burgdorferi, the causative agent of Lyme Disease, is cloned and exported to the outNeisseria gonorrhea, a bacterium that naturally turns over its outer membrane into easily isolated… More

LYME VACCINE BASED ON BORRELIA DECORIN ADHESIN

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$98,937.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

ADHESIN BASED VACCINE TO PREVENT URINARY TRACT INFECTION

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$99,969.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

LYME VACCINE BASED ON BORRELIA TRANSFERIN RECEPTORS

Award Year / Program / Phase:
1996 / SBIR / Phase I
Award Amount:
$99,931.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

LYME VACCINE BASED ON BORRELIA DECORIN ADHESIN

Award Year / Program / Phase:
1997 / SBIR / Phase II
Award Amount:
$750,000.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

ADHESIN BASED VACCINE TO PREVENT URINARY TRACT INFECTION

Award Year / Program / Phase:
1997 / SBIR / Phase II
Award Amount:
$748,501.00
Agency:
HHS
Principal Investigator:
Abstract:
N/a

CAPSOMERES AS BASIS FOR A HUMAN PAPILLOMAVIRUS VACCINE

Award Year / Program / Phase:
1998 / SBIR / Phase I
Award Amount:
$99,986.00
Agency:
HHS
Principal Investigator:
Suzich, Joann A
Abstract:
N/a